|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Norwegian University of Science and Technology |
|---|---|
| Collaborator: |
Sør-Trøndelag chapter of the Norwegian Physiotherapist Association |
| Information provided by: | Norwegian University of Science and Technology |
| ClinicalTrials.gov Identifier: | NCT00934830 |
Purpose
Question: Is the effect of therapeutic ultrasound equally effective to antibiotic for treatment of sinusitis? Design: A randomized clinical trial with concealed allocation, self-assessment by the subjects and intention-to-treat analysis.
| Condition | Intervention | Phase |
|---|---|---|
|
Sinusitis |
Drug: Antibiotic (Amoxicillin) Other: Therapeutic ultrasound |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Antibiotics Versus Therapeutic Ultrasound for Treatment of Sinusitis: a Randomized Clinical Trial |
| Enrollment: | 48 |
| Study Start Date: | January 2005 |
| Study Completion Date: | October 2008 |
| Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Antibiotic |
Drug: Antibiotic (Amoxicillin)
500 mg, 3 times per day for 10 days
|
| Experimental: Therapeutic ultrasound |
Other: Therapeutic ultrasound
1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days.
|
Subjects (n=48) with clinically diagnosed acute bacterial rhinosinusitis (ABRS)will included. The antibiotic group will receive amoxicillin (500 mg) 3 times per day for 10 days. The ultrasound group will receive therapeutic ultrasound over sinuses at 1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days. Improvement of symptoms (pain and congestion; numeric rating scale; 0-10) from day 1 to days 4 and 21 will be recorded. Relapses, side-effects and satisfaction with treatment will be assessed at one-year follow-up.
Eligibility| Ages Eligible for Study: | 15 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Responsible Party: | Ottar Vasseljen, associate professor, Norwegian University of Science and Technology |
| ClinicalTrials.gov Identifier: | NCT00934830 History of Changes |
| Other Study ID Numbers: | ELI-107-04(REK) |
| Study First Received: | July 6, 2009 |
| Last Updated: | August 9, 2011 |
| Health Authority: | Norway: Ethics Committee |
|
Antibiotic Ultrasound Efficacy Treatment |
|
Sinusitis Paranasal Sinus Diseases Nose Diseases Respiratory Tract Diseases Respiratory Tract Infections Otorhinolaryngologic Diseases |
Amoxicillin Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |